抗凝、新型药物与手术：我们能否原谅这种干扰？ - Suppr | 超能文献

Anticoagulation, novel agents, and procedures: can we pardon the interruption?

作者信息

Garcia David A, Granger Christopher B

出版信息

Circulation. 2012 Jul 17;126(3):255-7. doi: 10.1161/CIRCULATIONAHA.112.115188. Epub 2012 Jun 14.

DOI:10.1161/CIRCULATIONAHA.112.115188

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Anticoagulation, novel agents, and procedures: can we pardon the interruption?抗凝、新型药物与手术：我们能否原谅这种干扰？

Circulation. 2012 Jul 17;126(3):255-7. doi: 10.1161/CIRCULATIONAHA.112.115188. Epub 2012 Jun 14.

2

Letter by David et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) Randomized Trial".

Circulation. 2013 Mar 19;127(11):e504. doi: 10.1161/CIRCULATIONAHA.112.133041.

3

Letter by Hjemdahl et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial".

Circulation. 2013 Mar 19;127(11):e505. doi: 10.1161/CIRCULATIONAHA.112.135343.

4

Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”.

Circulation. 2013 Mar 19;127(11):e506. doi: 10.1161/circulationaha.112.154732.

5

Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.与华法林相比，达比加群的围手术期出血和血栓栓塞事件：来自随机评估长期抗凝治疗（RE-LY）随机试验的结果。

Circulation. 2012 Jul 17;126(3):343-8. doi: 10.1161/CIRCULATIONAHA.111.090464. Epub 2012 Jun 14.

6

The importance of postapproval data for dabigatran.达比加群批准后数据的重要性。

JAMA Intern Med. 2015 Jan;175(1):25. doi: 10.1001/jamainternmed.2014.6265.

7

Complications associated with oral anticoagulation therapy.

Adv Emerg Nurs J. 2013 Oct-Dec;35(4):283-6. doi: 10.1097/TME.0b013e3182a9e9a2.

8

Dabigatran: uncharted waters and potential harms.达比加群：未知领域与潜在危害。

Ann Intern Med. 2012 Jul 3;157(1):66-8. doi: 10.7326/0003-4819-157-1-201207030-00467.

9

Intensity and quality of warfarin anticoagulation in Chinese patients: setting the record straight.中国患者华法林抗凝治疗的强度与质量：澄清事实

Stroke. 2015 Jan;46(1):5-6. doi: 10.1161/STROKEAHA.114.007486. Epub 2014 Nov 18.

10

Dabigatran and postmarketing reports of bleeding.达比加群与上市后出血报告。

N Engl J Med. 2013 Apr 4;368(14):1272-4. doi: 10.1056/NEJMp1302834. Epub 2013 Mar 13.

引用本文的文献

1

The new oral anticoagulants: practical management for patients attending for endoscopic procedures.新型口服抗凝剂：接受内镜检查患者的实际管理

Frontline Gastroenterol. 2013 Jul;4(3):213-218. doi: 10.1136/flgastro-2013-100325. Epub 2013 Apr 11.

2

Clinical diseases with thrombotic risk and their pharmacologycal treatment: how they change the therapeutic attitude in dental treatments.具有血栓形成风险的临床疾病及其药理学治疗：它们如何改变牙科治疗中的治疗态度。

Med Oral Patol Oral Cir Bucal. 2013 Nov 1;18(6):e888-95. doi: 10.4317/medoral.19561.